Clinical trial · Observational
Clinical Utilization of Newly Approved Oncology Medications
Clinical Utilization of Newly Approved Oncology Medications in Middle Eastern Population
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The efficacy and safety of different medications vary from one individual to another and from one ethnic group to another. Therefore, strong interest in the study of pharmacogenomic and pharmacoepidemiology has evolved recently. There are multiple examples of oncology drugs being more effective in certain ethnic population compared to other. For example, irinotecan combined with cisplatin was very effective drug in the management of small cell lung cancer in the Japanese patients while an identical study done in the US revealed no major benefit to this combination in American population
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| immunotherapy | Drug | Immunotherapy | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Descriptive measures of the pattern of use of the new medications in our population
- timeFrame
- 3 years
Secondary outcomes (3)
- measure
- Measuring the efficacy in terms of response
- timeFrame
- 3 years
- measure
- Measuring the efficacy in terms of progression-free survival (PFS)
- timeFrame
- 3 years
- measure
- Measuring the efficacy in terms of overall survival (OS)
- timeFrame
- 3 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * All patients with cancer or hematological malignancies receiving new oncology medications (defined as a medication in the first five years of their introduction to the ME market * Patient accepts to participate in study and signing consent form Exclusion Criteria: * None
References
Publications (0)
Data not yet available